who should not take glp 1 receptor agonists Independent Nurse - GLP-1 and GIP/GLP-1 for type 2 diabetes Struggling with GLP-1 therapy side

doi: 10.3233/JAD-170364 44 GovindpaniKTurnerCWaldvogelHJFaullRLMKwakowskyA

avoid freezing

Medications that can enhance the activity of insulin (so-called incretin mimetics) can help to overcome insulin resistance caused by SGAs (and potentially by other psychotropic medications) and essentially lead to weight loss through enhanced fuel efficiency. Metformin, typically dosed up to 1,000 mg twice daily with meals, has increasingly become recognized as a first-line strategy to attenuate weight gain and glycemic dysregulation from SGAs via its ability to reduce insulin resistance

25 Conclusions Understanding the enteroinsular axis has been the basis of seminal advancements in the therapeutic approach to diabetes management, with translation of research discoveries into effective pharmacologic therapies

The drugs, including semaglutide (Ozempic, Wegovy and Rybelsus), tirzepatide (Mounjaro and Zepbound) and retatrutide (still in clinical trials), are used to treat both diabetes and obesity

Your healthcare provider will tell you when and how often to take your medication (usually injections)